Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues

Area of Science:

• Pediatric Hematology
• Thromboembolic Disease Management
• Pharmacology in Children

Background:

• Children with thromboembolic disease face unique challenges in anticoagulant prophylaxis and treatment.
• Current evidence for optimal management in pediatric populations is limited, with few interventional studies.
• Existing observational studies identify risk factors but lack robust data on thromboprophylaxis in specific pediatric subgroups.

Purpose of the Study:

• To review challenges in pediatric anticoagulant therapy.
• To highlight research needs for improving outcomes in children with thromboembolic disease.
• To propose a risk-based framework for thromboprophylaxis and discuss novel anticoagulants.

Main Methods:

• Literature review of existing evidence on pediatric anticoagulation.
• Analysis of current anticoagulant agents (heparin, warfarin) and their limitations in children.
• Discussion of emerging direct oral anticoagulants (DOACs) and ongoing pediatric studies.

Main Results:

• Significant gaps exist in evidence for pediatric anticoagulant prophylaxis and treatment.
• Weight-based dosing of traditional anticoagulants shows acceptable outcomes, but monitoring and target ranges are not well-established.
• Direct oral anticoagulants (DOACs) show promise for pediatric use, with ongoing studies to determine benefit-risk balance.

Conclusions:

• Optimizing anticoagulant therapy in children requires addressing unique age-specific challenges.
• Further research is essential to refine risk stratification and evaluate novel anticoagulants like DOACs.
• Establishing age-specific dosing and safety profiles for DOACs is crucial for pediatric thromboembolic disease management.